ALERT-- New Product Approval-Feline Heartworm-Only kit on the Market!!
Synbiotics Corp. Gains Approval For New Product
SAN DIEGO--(BUSINESS WIRE)--Jan. 6, 1998--Synbiotics Corp.
(NASDAQ:SBIO) Tuesday announced that it has received regulatory
approval to market ASSURE/FH, a proprietary diagnostic test to detect
antibody against heartworm infection in cats.
Synbiotics' customers will begin receiving shipments in a few days.
Synbiotics' ASSURE/FH is the first product in the United States to offer veterinarians a simple and accurate way to test cats in the vet's office for exposure to the heartworm parasite. Previously, this infection could only be reliably detected by sending blood samples to a laboratory.
Heartworm, a parasite carried by mosquitos, is widely known as an infection in dogs; its diagnosis, prevention and treatment represent an important aspect of veterinary practice and a major market in animal health. While cats are infected less often than dogs, the effects of feline heartworm can be severe, even fatal, and can occur without warning. It's for this reason that feline heartworm infection is of rising concern to veterinarians and owners of the more than 60 million cats in the United States.
According to Dr. Mike Harrod, Synbiotics' director of veterinary services: "Heartworm can be dangerous, even fatal, to cats who may exhibit no apparent signs of illness. With simple, rapid testing now available in the vet's office, cat owners should consult with their veterinarians about regular testing and preventive medication."
Ken Cohen, Synbiotics' president and chief executive officer, added:
"Canine heartworm testing provides a great benefit to dogs and their
owners, and a strong contribution to Synbiotics' business. With the cat population outnumbering that of dogs and the growing awareness of feline heartworm, our innovative development and launch of ASSURE/FH offers the potential for substantial value to our customers and to our company."
Synbiotics develops, manufactures and markets animal health products
under its own name in the United States and internationally through
licensees.
With the exception of historical matters, the issues discussed in this press release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including competition from larger companies, reliance on third-party manufacturers and distributors, possible technology improvements by others, intellectual property rights issues, the ability to assimilate acquired businesses, the seasonality of major portions of the company's business and other risks set forth in the company's
filings with the Securities and Exchange Commission, particularly Form
10-KSB filed for the year ended Dec. 31, 1996 and Form 10 QSB filed for the quarter ended Sept. 30, 1997. Actual results may differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of the release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
CONTACT: Synbiotics Corp.
Michael K. Green, 619/451-3771
mikeg@synbiotics.com
or
Kenneth M. Cohen, 619/451-3771
kenc@synbiotics.com
or
Financial Relations Board
Fiona Ross, 310/442-0599
or
Kathy Brunson, 312/266-7800 |
